Evidence map›Paper›PMID 36018052›Full record

ArticleAmerican journal of clinical pathology2022

Dysmegakaryopoiesis and Transient Mild Increase in Bone Marrow Blasts in Patients With Aplastic Anemia Treated With Eltrombopag May Be Signs of Hematologic Improvement and Not Portend Clonal Evolution.

Akira Matsuda, Kazunori Imada, Naoshi Obara, Hiroatsu Iida, Hirohito Yamazaki, Yoshiaki Tomiyama, Koichi Miyamura, Osamu Sasaki, Tetsuo Maeda, Kensuke Ohta and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of clinical pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

Akira MatsudaDepartment of Hemato-Oncology and Medical Education, Saitama International Medical Center, Saitama Medical University, SaitamaJapan.
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Naoshi ObaraDepartment of Hematology, University of Tsukuba, Tsukuba, Japan.
Hiroatsu IidaDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Hirohito YamazakiDivision of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Yoshiaki TomiyamaDepartment of Hematology and Oncology, Osaka University Hospital, Osaka, Japan.
Koichi MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.
Osamu SasakiDepartment of Hematology, Miyagi Cancer Center, Natori, Japan.
Tetsuo MaedaDepartment of Hematology, Suita Municipal Hospital, Suita, Japan.
Kensuke OhtaHematology Ohta Clinic, Shinsaibashi, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Yukihiro TokumineDepartment of Hematology, Itami City Hospital, Itami, Japan.
Kenji ImajoDepartment of Hematology, Okayama City Hospital, Okayama, Japan.
Yuji OkamotoNovartis Pharma, Tokyo, Japan.
Mami MurakamiNovartis Pharma, Tokyo, Japan.
Shinji NakaoKanazawa University Institute of Medical Pharmaceutical and Health Sciences, Kanazawa, Japan.
Novartis (Japan) · JPItami City Hospital · JPJapanese Red Cross Nagoya Daiichi Hospital · JPKanazawa University · JPKanazawa University Hospital · JPMiyagi Prefectural Hospital Organization · JPNagoya Medical Center · JPNTT Medical Center · JPOkayama Prefecture · JPOsaka Hospital · JPOsaka University Hospital · JPSaitama Medical University · JPSuita Municipal Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEltrombopag, a thrombopoietin-receptor agonist, stimulates hematopoiesis in patients with acquired aplastic anemia (AA). Cytomorphologic changes in bone marrow after eltrombopag administration are still unclear. This study examined the effect of eltrombopag on cytomorphologic findings using data from prior phase 2 studies (E1201 and E1202).

methodsMicroscopic examinations were performed in 31 patients with AA (E1201 [n = 21], E1202 [n = 10]). The relationship between hematologic improvement and morphologic findings was also investigated.

resultsIn 5 patients (E1201 [n = 3], E1202 [n = 2]), the bone marrow blast count increased after initiation of eltrombopag treatment compared with screening values. The blast count was less than 5%, and the increase in bone marrow blasts was transient in all 4 patients who had bone marrow examinations at follow-up. In 8 patients (E1201 [n = 5], E1202 [n = 3]), dysplastic forms of megakaryocytes were found in the bone marrow following treatment initiation. Dysmegakaryopoiesis of 10% or more was found in 3 patients. None of the patients revealed micromegakaryocytes. Ten patients showed an increase in bone marrow blasts and/or dysmegakaryopoiesis following treatment initiation. Nine of 10 patients showed hematologic improvement in 1 or more lineages.

conclusionsDysmegakaryopoiesis without micromegakaryocytes and a transient increase of less than 5% in bone marrow blast count may be signs of hematologic improvement with eltrombopag for patients with AA.

Indexed as

Anemia, AplasticBenzoatesBone MarrowClonal EvolutionHumansHydrazinesPyrazolesReceptors, ThrombopoietinBenzoateseltrombopagHydrazinesPyrazolesReceptors, ThrombopoietinAplastic anemiaBlast countBone marrowDysmegakaryopoiesisEltrombopagHematologic improvement

Identifiers

PMID36018052
PMCPMC9631234
OpenAlexW4293116621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.